TG Therapeutics Q3 Earnings, Revenue Fall

MT Newswires Live11-04 20:37

TG Therapeutics (TGTX) reported Q3 earnings Monday of $0.02 per diluted share, down from $0.73 a year earlier.

Analysts polled by Capital IQ expected $0.03.

Revenue for the quarter ended Sept. 30 was $83.9 million, down from $165.8 million a year earlier.

Analysts surveyed by Capital IQ expected $81.7 million.

For 2024, the company said it now expects Briumvi US net product revenue of $300 million to $305 million, compared with the prior guidance of $290 million to $300 million. Analysts polled by Capital IQ expect $327.8 million in revenue.

As of Sept. 30, the company said it had $341 million in cash, cash equivalents and investment securities, which it expects could fund operations through its current operating plan.

Price: 23.60, Change: -3.30, Percent Change: -12.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment